Podcast
MSL Talk: Tom Caravela
COMP: How HR Determines Compensation and Titles for Job Offers
Summary
In this episode, Chris Castin joins Tom Caravela to delve into the intricacies of compensation and negotiation processes for MSL roles. They explore how to prepare for job offer negotiations while emphasizing the importance of transparency and the risks of over-negotiating. Chris provides insights into HR perspectives and how offers are determined using formulas and data, highlighting the significance of internal equity. The discussion covers the role of job titles, leveling, and the impact of experience on role effectiveness. They also analyze written job offers, discuss sign-on bonuses, and offer advice on responding to offers with effective negotiation strategies. The episode concludes with practical advice for MSLs navigating job offers.
My guest today is Chris Castin, Senior Director, Talent Acquisition NKARTA Therapeutics and we discuss how HR departments determine compensation and titles for job offers
Chris shares…
👉 The HR formula for determining job offers
👉 What you need to know to negotiate an offer
👉 What information is expected in advance of the job offer
👉 How and why sign-on bonuses are used
👉 The way HR determines titles and leveling
MSL job negotiation, HR compensation strategies, job offer negotiation tips, internal equity in job offers, sign-on bonuses in employment
Related Topics
You May Also Like
MSL Talk: Tom Caravela
Article
Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
Podcast
Michael Pietrack
Hiring Managers Beware: Reverse Rejection Explained!
Article
Jamie Riley
The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies — and a Call to Candidates
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Forbes Books Press Release Official